Lantern Pharma Inc. (LTRN)

Pharmaceutical Preparations · market cap $18M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-11 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Lantern Pharma (LTRN) is a micro-cap oncology company with a $35M market cap and 24 employees, running Phase 2 trials for lead asset LP-184 in Advanced Solid Tumors and LP-300 in Adenocarcinoma of Lung. The company carries only $4.9M in cash, implying roughly 3.9 months of runway, making near-term financing risk the dominant variable in the investment calculus.

The catalyst path

2026-11-11 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
LP-184	Phase 2	Advanced Solid Tumor
LP-300	Phase 2	Adenocarcinoma of Lung

Price & technical context

3-month

-74.8%

6-month

-29.6%

12-month

-77.0%

52-wk range

$1.00–$4.62

vs 50-day MA

-52.5%

vs 200-day MA

-63.4%

Realized vol

106.1%

Max drawdown

-81.5%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for LTRN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.